Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | ACE | P12821 | 6/20 | 0.44 |
| ▸ | F2 | P00734 | 1/20 | 0.44 |
| ▸ | REN | P00797 | 1/20 | 0.41 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.39 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30116344 | 0.93 | ACE (0.47) | OPRM1ACEF2NTSR2NTSR1 | |
| SCHEMBL30395076 | 0.93 | ACE (0.49) | OPRM1ACERENNTSR2NTSR1 | |
| SCHEMBL29377499 | 0.92 | ACE (0.47) | OPRM1ACEF2RENOPRD1 | |
| SCHEMBL29765114 | 0.90 | ACE (0.48) | OPRM1ACEF2RENOPRD1 | |
| SCHEMBL31097656 | 0.90 | OPRM1 (0.49) | OPRM1ACEF2RENNTSR2 | |
| SCHEMBL29379729 | 0.90 | ACE (0.47) | OPRM1ACEF2RENOPRK1 | |
| SCHEMBL7760126 | 0.89 | ACE (0.53) | ACERENNTSR2NTSR1OPRK1 | |
| SCHEMBL29590494 | 0.86 | OPRM1 (0.51) | OPRM1ACEF2NTSR2NTSR1 | |
| SCHEMBL30892637 | 0.85 | OPRM1 (0.54) | OPRM1ACEF2NTSR2NTSR1 | |
| SCHEMBL30040838 | 0.85 | ACE (0.49) | OPRM1ACERENOPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12599675-B2 | Conjugate of immune-stimulating il-2 analog and preparation method thereof | HANMI PHARM. CO., LTD. (KR) | 2026-04-14 | — | — | US | disclosed |
| EP-4230219-B1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | HANMI PHARMACEUTICAL CO LTD (KR) | 2026-04-08 | — | — | EP | disclosed |
| US-12558431-B2 | Method of preparing protein conjugate | HANMI PHARM. CO., LTD. (KR) | 2026-02-24 | — | — | US | disclosed |
| US-12552850-B2 | GLP-1/GIP dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same | HANMI PHARM. CO., LTD. (KR) | 2026-02-17 | — | — | US | disclosed |
| EP-4678181-A1 | COMBINATION THERAPY OF INTERLEUKIN-2 ANALOG OR CONJUGATE THEREOF AND IMMUNE CHECKPOINT INHIBITOR FOR PREVENTION OR TREATMENT OF CANCER | Hanmi Pharm. Co., Ltd. (KR) | 2026-01-14 | — | — | EP | disclosed |
| EP-4678180-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING CANCER INCLUDING INTERLEUKIN 2 ANALOG OR CONJUGATE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2026-01-14 | — | — | EP | disclosed |
| US-12491258-B2 | Method for preparing long-acting drug conjugate through preparation of intermediate | HANMI PHARM. CO., LTD. (KR) | 2025-12-09 | — | — | US | disclosed |
| EP-4640234-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GRAFT-VERSUS-HOST DISEASE CONTAINING GLP-2 DERIVATIVE OR LONG-ACTING CONJUGATE THEREOF | Hanmi Pharm. Co., Ltd. (KR) | 2025-10-29 | — | — | EP | disclosed |
| US-20250276044-A1 | COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE | HANMI PHARM. CO., LTD. (KR) | 2025-09-04 | — | — | US | disclosed |
| EP-4556488-A2 | NOVEL METHOD FOR PREPARING LONG-ACTING DRUG CONJUGATE THROUGH PREPARATION OF INTERMEDIATE | Hanmi Pharm. Co., Ltd. (KR) | 2025-05-21 | — | — | EP | disclosed |
| WO-2022080986-A1 | GLP-1/GIP DUAL AGONIST, LONG-ACTING CONJUGATE THEREOF, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 한미약품 주식회사 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022080985-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES COMPRISING GIP DERIVATIVE OR LONG-ACTING CONJUGATE THEREOF | 한미약품 주식회사 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022080989-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES | 한미약품 주식회사 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022080987-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING VASCULITIS | 한미약품 주식회사 | 2022-04-21 | — | — | WO | disclosed |
| WO-2022065898-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BONE DISEASES, COMPRISING TRIPLE AGONIST OR CONJUGATE THEREOF HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1 AND GLP RECEPTORS | 한미약품 주식회사 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022065897-A1 | THERAPEUTIC USE, FOR NEURODEGENERATIVE DISEASES, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF | 한미약품 주식회사 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022065899-A1 | THERAPEUTIC USE OF LONG-ACTING CONJUGATE OF TRIPLE AGONIST ACTING ON ALL OF GLUCAGON, GLP-1 AND GIP RECEPTORS AGAINST MULTIPLE SCLEROSIS | 한미약품 주식회사 | 2022-03-31 | — | — | WO | disclosed |
| WO-2022035302-A1 | HYPOTENSIVE PHARMACEUTICAL COMPOSITION COMPRISING TRIPLE ACTIVATOR HAVING ACTIVITY FOR ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS | 한미약품 주식회사 | 2022-02-17 | — | — | WO | disclosed |
| WO-2022035271-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A TRIPLE-ACTIVATOR PERSISTENT CONJUGATE AS ACTIVE INGREDIENT | 한미약품 주식회사 | 2022-02-17 | — | — | WO | disclosed |
| US-20220040262-A1 | THERAPEUTIC USE OF TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF FOR LIVER DISEASE | HANMl PHARM. CO., LTD. (KR) | 2022-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250276044-A1 | COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE | IAPP, GLP1R, VIP | OPRM1 2443/4885ACE 3564/4885F2 2314/4885 |
| US-12491258-B2 | Method for preparing long-acting drug conjugate through preparation of intermediate | GNRHR, UGT1A7, UGT1A3 | OPRM1 238/4885ACE 492/4885F2 931/4885 |
| US-12552850-B2 | GLP-1/GIP dual agonist, long-acting conjugate thereof, and pharmaceutical composition comprising same | GLP1R, VIP, GIPR | OPRM1 1089/4885ACE 4565/4885F2 2432/4885 |
| US-20220040262-A1 | THERAPEUTIC USE OF TRIGONAL GLUCAGON/GLP-1/GIP RECEPTOR AGONIST OR CONJUGATE THEREOF FOR LIVER DISEASE | GLP1R, GIPR, GCGR | OPRM1 2396/4885ACE 3751/4885F2 2999/4885 |
| US-12599675-B2 | Conjugate of immune-stimulating il-2 analog and preparation method thereof | IL2, IL2RA, ILF2 | OPRM1 845/4885ACE 4348/4885F2 135/4885 |
| US-12558431-B2 | Method of preparing protein conjugate | GLP1R, GIPR, GCGR | OPRM1 918/4885ACE 4643/4885F2 748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.